Pathway Alterations in Stage II/III Primary Melanoma.
Caroline E KostrzewaLi LuoArshi AroraVenkatraman E SeshanMarc S ErnstoffSharon N EdmistonKathleen ConwayIvan GorlovKlaus BusamIrene OrlowEva Hernando-MongeNancy E ThomasMarianne BerwickColin B BeggRonglai Shennull nullPublished in: JCO precision oncology (2023)
Our results confirm the dominance of mutations in the RTK-RAS pathway. The presence of many mutations in several well-known, actionable pathways suggests potential avenues for targeted therapy in these early-stage cases.